TB-500
TB-500 circulates online as a "synthetic fragment of thymosin beta-4" supposedly speeding up healing of tendons, ligaments, and muscle — in practice, a marketing name for a poorly defined substance with not a single published human clinical trial behind it.
Number of studies
3
Safety
Requires caution
Time to effects
Not established in human clinical trials — "time to effect" figures quoted on forums (usually 2–6 weeks) are anecdotal reports unsupported by objective measurement or a control group.
Monthly cost
ok. 300–800 zł/miesiąc przy typowych protokołach stosowanych przez użytkowników forów
Price in Poland
ok. 150–400 zł za fiolkę 2–5 mg w nieregulowanej sprzedaży internetowej
Who it's for
Cena nie jest wskaźnikiem jakości, czystości ani skuteczności — rynek jest całkowicie nieregulowany i brak niezależnej weryfikacji zawartości fiolek u większości dostawców.
Indicative prices for the Polish market — we don't point to specific retailers; the real price depends on the manufacturer, form and place of purchase.
Table of contents
TL;DR
TB-500 circulates online as a "synthetic fragment of thymosin beta-4" supposedly speeding up healing of tendons, ligaments, and muscle — in practice, a marketing name for a poorly defined substance with not a single published human clinical trial behind it.
- →In animal studies and cell cultures, full-length thymosin beta-4 speeds fibroblast and keratinocyte migration into a wound
- →Confirmed pro-angiogenic activity (new blood vessel formation) in preclinical models
- →Some preclinical data point to modulation of excessive inflammatory response in the early phase of tissue healing
| What it is | Marketing name for a presumed synthetic fragment of thymosin beta-4 (the LKKTET sequence) |
|---|---|
| Reference full molecule | Thymosin beta-4 (Tβ4) — a natural 43-amino-acid actin-sequestering protein |
| Human evidence level | Practically none — zero published clinical trials of TB-500 itself |
| Regulatory status | Not approved as a drug or dietary supplement; sold as a "research use only" compound |
| Status in sport | Peptide hormone/growth factor category banned by WADA year-round |
| Route of administration in practice | Subcutaneous injection — without medical oversight, without quality control of the product |
Understand
Overview
TB-500 is the trade name for a substance sold online as a synthetic regenerative peptide, marketed as accelerating the healing of tendons, ligaments, muscle, and skin. The marketing relies on a shortened, simplified scientific history: in the 1970s and 1980s, researchers isolated a protein called thymosin beta-4 (Tβ4) from thymus tissue — a naturally occurring 43-amino-acid peptide in the human body that regulates actin dynamics, the cytoskeletal protein central to cell migration during wound healing. TB-500 is presented as a synthetic version or "active fragment" of this molecule — but that is exactly where the real scientific precision problems begin.
The issue is that the term "TB-500" has no single, settled chemical definition in the scientific literature. Sellers typically describe it as corresponding to the LKKTET sequence (residues 17–23 of full-length thymosin beta-4), responsible for actin binding — but products sold under this name vary in practice and have unconfirmed, non-standardized content. No peer-reviewed publication exists with a consistent, reproducible pharmacological characterization of a compound actually matching what is bought online as "TB-500" — a fundamental difference from substances with established chemical nomenclature.
All of the enthusiasm around TB-500 grew out of decades of research on full-length thymosin beta-4, not the short fragment itself. The pharmaceutical company RegeneRx Biopharmaceuticals ran several Phase II clinical trials between 2007 and 2011 using the full, 43-amino-acid thymosin beta-4 (the RGN-137 preparation) in chronic venous ulcers, pressure sores, and wounds in patients with epidermolysis bullosa — some of these trials gave promising, though inconclusive, healing signals without significant adverse effects. None of these trials, however, involved the short fragment sold as TB-500, none involved tendons or ligaments, and RGN-137 never obtained drug registration; its clinical development was ultimately halted.
The most current and systematic literature review on the topic — a 2026 scoping review that searched PubMed, Europe PMC, and ClinicalTrials.gov through March 2026 and identified 80 eligible publications — explicitly states that direct studies of TB-500 itself (as opposed to full-length thymosin beta-4) are a mere handful, with most evidence coming from in vitro and animal studies. The authors note that musculoskeletal tissue categories — tendon, ligament, muscle — exactly the indications TB-500 is most heavily promoted for in biohacking and sports circles — are represented only sparsely in the literature, and direct human evidence for TB-500 itself was limited to a single identified study.
TB-500 is not a registered drug, a legal dietary supplement, or a substance with any settled regulatory status in Poland, the EU, or the United States. It is sold exclusively by online vendors as a "research use only" compound — a label that functions in practice as a legal loophole bypassing drug regulation, not as confirmation of any quality control, sterility, or purity of the product reaching the customer. We cover the mechanics of this gray market, and documented risks from it, more broadly in our article on peptide therapy.
The group most at risk of encountering TB-500 are amateur and competitive athletes seeking faster recovery from tendon and ligament injuries, along with bodybuilding and biohacking communities looking for a regenerative edge. It's worth knowing that the broad category of peptide hormones and growth factors it is sometimes grouped with sits on the World Anti-Doping Agency's (WADA) year-round prohibited list — detection in doping control carries sanctions regardless of therapeutic intent or where the product was purchased.
History of use
Thymosin beta-4 was first isolated from calf thymus tissue in the 1970s by Allan Goldstein's team, originally in a search for immunomodulatory factors. Decades later, in the 1990s and 2000s, research shifted toward its role in tissue healing and cell migration, leading to a series of Phase II clinical trials sponsored by RegeneRx Biopharmaceuticals on the full molecule for chronic ulcers and wounds — none ended in drug registration. "TB-500" as a commercial product appeared in online commerce in the latter half of the 2000s, alongside the rising popularity of BPC-157 and other "research peptides," and has never been subject to independent, systematic registration or regulatory standardization of its definition.
Mechanism of action
The mechanism attributed to TB-500 derives from the well-described biology of full-length thymosin beta-4, not from studies of the short fragment itself. Tβ4 is the main intracellular protein sequestering actin monomers (G-actin), letting it regulate the dynamic balance between globular and filamentous (F-) actin — a process fundamental to cell migration, shape, and the ability to move toward a site of tissue damage. Animal models and cell cultures have shown that Tβ4 speeds keratinocyte and fibroblast migration into a wound, stimulates angiogenesis (new blood vessel formation) via endothelial cell activation, and modulates the inflammatory response, partly limiting excessive neutrophil infiltration in the early phase of healing.
The theoretical rationale for the LKKTET fragment (the presumed basis of TB-500) rests on the observation that this short amino-acid sequence within the full Tβ4 molecule is responsible for actin binding — hence the marketing claim that a "concentrated" fragment should retain the key biological activity of the whole protein in a smaller molecule and (theoretically) at lower production cost. The problem is that removing a fragment from the context of the full 43-amino-acid protein structure can materially change its stability, half-life, receptor binding behavior, and ultimate biological activity — the extrapolation "the fragment acts like the whole" is not automatically true in peptide pharmacology and requires separate verification, which for TB-500 has not, in practice, been carried out systematically.
A 2024 study using high-resolution mass spectrometry (UHPLC-Q-Exactive Orbitrap) to analyze TB-500 and its metabolites in vitro and in rats is one of the few that actually attempted to characterize the pharmacokinetics and biological activity of the substance actually sold under this name, rather than full-length thymosin beta-4. The authors confirmed pro-healing activity in in vitro assays, but the study did not involve humans, did not assess tendon or ligament healing, and does not settle the question of real-world effectiveness in a patient with a sports injury.
Specifically regarding tendons, it's worth distinguishing evidence for TB-500/Tβ4 from the far more frequently cited studies on BPC-157, a separate peptide with a different mechanism (mainly pro-angiogenic and related to the nitric oxide axis), covered more extensively in our BPC-157 entry and in our article on combining both peptides. The two compounds are often confused or stacked together in gray-market "regenerative" protocols despite their presumed mechanisms being distinct and never having been formally compared in a human clinical trial.
G-actin sequestration
Full-length thymosin beta-4 binds monomeric actin, regulating the balance between its globular and filamentous forms inside the cell.
Cytoskeletal mobilization
This shift in balance lets cells (fibroblasts, keratinocytes, endothelial cells) change shape and migrate toward damaged tissue.
Presumed LKKTET fragment activity
The short sequence responsible for actin binding within the full molecule is the basis of the marketing claim about TB-500's activity — never systematically verified for the fragment itself in humans.
Modulation of inflammation and angiogenesis
In animal studies, full-length Tβ4 limits excessive inflammatory response and stimulates new blood vessel formation in healing tissue.
Evidence: limited — based on 3 studies in this database.
Benefits
Common myths
MythTB-500 is just another name for thymosin beta-4, so decades of research on the latter can be directly translated into TB-500's effectiveness.
FactTB-500 is a marketing name for a presumed short fragment of the full, 43-amino-acid thymosin beta-4. Removing a fragment from the context of the whole molecule can materially change its stability and biological activity — extrapolating from studies of the full protein to the fragment alone is not scientifically justified without separate verification, which in practice has not been carried out.
MythSince thymosin beta-4 is a natural body protein, TB-500 must be safe.
FactThe product sold online as TB-500 is a synthetic substance manufactured under unregulated conditions, administered in doses and by a route (subcutaneous injection) unrelated to the natural, intracellular occurrence of thymosin beta-4. Lack of regulatory oversight means a lack of required toxicology studies and no standardization of product purity.
MythThere are clinical trials confirming TB-500's effectiveness for tendon healing in humans.
FactThe most current systematic literature review, from 2026, did not identify any clinical trial assessing TB-500 itself for tendon or ligament healing in humans — direct evidence on TB-500 was limited to a single study of a different nature.
MythA "research use only" label means a high-quality product intended for professional laboratories.
FactIn practice this is a legal loophole letting sellers bypass drug regulations, not confirmation of quality. Independent analyses of products from this market segment have repeatedly found contamination and mismatches between vial content and label.
MythTB-500 and BPC-157 work the same way, so combining them simply doubles the effect.
FactThe two peptides have distinct, never jointly verified mechanisms of action (presumed actin sequestration for TB-500 versus mainly pro-angiogenic action for BPC-157) — no clinical trial has assessed their combined use in humans, as we cover more extensively in a separate article.
MythThe 2–2.5 mg twice-weekly dosing repeated across forums has a basis in pharmacokinetic studies.
FactNo published human pharmacokinetic study of TB-500 exists on which such recommendations could be based — it is an extrapolation from anecdotal user reports and doses used in animal models, not a scientific finding.
Forms & variants
TB-500 comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Lyophilized powder (2–5 mg vial)
The most common form sold as "TB-500" — requires self-dissolution in bacteriostatic water, with no guarantee of sterility for a process carried out outside pharmaceutical conditions.
Best for: No use recommended by our editorial team — descriptive market information only
Combined preparations with BPC-157 ("stack")
Ready-made blends of both peptides in a single vial, marketed as mutually reinforcing regenerative action — without clinical trials assessing such a combination.
Best for: No use recommended by our editorial team — descriptive market information only
Full-length thymosin beta-4 (historical RGN-137 research product)
A separate, far better characterized molecule tested in Phase II clinical trials for chronic wounds — clinical development halted, never registered as a drug, not commercially available as a finished product.
Best for: Historical and scientific context only — not a product available for purchase
For active people
Training regularly? Check your supplement profile.
Sleep, diet, training frequency, and recovery all matter. Answer a few questions and see which supplements might make the most sense for you.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
Thymosin beta-4 is a naturally occurring, well-characterized 43-amino-acid protein in the body. TB-500 is a trade name for a presumed shorter, synthetic fragment of that molecule, with no single consistent chemical definition in the scientific literature and no systematic verification of whether it retains the full protein's biological activity.
Not in a way that would support effectiveness claims. The most current scoping review from 2026 identified just one study directly concerning TB-500 itself among 80 reviewed publications — the rest of the evidence concerns full-length thymosin beta-4 or animal and cell models.
It is not registered as a drug or approved as a dietary supplement in Poland or the EU. It is sold by online vendors with a "research use only" label, which is not confirmation of legality for human health or sports use.
They should not — the broad peptide hormone/growth factor category sits on the World Anti-Doping Agency's (WADA) year-round prohibited list. Detection in doping control carries sanctions regardless of therapeutic intent or declared regenerative purpose.
Not in the form of a clinical trial — no published study has assessed this specific combination in humans. The theoretical rationale (distinct, complementary mechanisms) is a hypothesis drawn from separate animal studies of each peptide, not proof of synergy. We cover this in more depth in a dedicated article on the combination.
Probably the best-documented risk across the entire category of unapproved "research" peptides is the lack of quality control of the product — independent lab analyses of products from this market segment have repeatedly found bacterial endotoxin contamination and mismatches between declared vial content and reality, regardless of whether the pure molecule itself would be safe.
No. Despite going through Phase II clinical trials for chronic ulcers and wounds, the RGN-137 preparation never obtained drug registration from any major agency, and its further clinical development was halted. This is not the same substance as the TB-500 currently sold online.
Dosage & timing
Typical dose
No approved, clinically evidence-based dosing guidelines for humans exist. Protocols found on internet forums (typically around 2–2.5 mg twice weekly) are extrapolations from anecdotal practice and doses used in animal studies, not findings supported by human pharmacokinetic research.
Form
In online commerce: lyophilized powder for self-dissolution and subcutaneous injection — with no standardization of purity or concentration between vendors
Dosing information reflects ranges reported in cited studies and online use for informational purposes only — it does not replace consultation with a doctor or pharmacist.
Best times to take it
- No studied, verified time-based administration schedules exist for humans — any "protocols" found online are informal and unapproved
What to combine with
Use caution with
Melanotan II — No interaction studies exist whatsoever — combining unapproved peptides with different mechanisms compounds total, unstudied risk
Safety
Side effects & contraindications
Possible side effects
No systematically collected data on TB-500's adverse effects in humans — virtually all available information comes from anecdotal user reports, not clinical trials
Anecdotally reported: dizziness, redness and swelling at the injection site, headaches, transient fatigue after injection
Theoretical risk of excessive, uncontrolled angiogenesis — relevant especially for people with a cancer history, given the mechanism of action of the reference molecule
Risk of local and systemic infection from self-injecting a product of unknown purity and sterility
Documented in lab analyses of gray-market products: bacterial endotoxin contamination, mismatch between declared and actual vial content
No data whatsoever on long-term safety — potential risks are largely theoretical, derived from the mechanism of action rather than clinical observation
Contraindications
History of cancer or elevated oncological risk — due to the theoretical risk of excessive angiogenesis
Pregnancy and breastfeeding — no safety data of any kind
Athletes subject to doping control — the peptide hormone/growth factor category is banned by WADA year-round
Anyone unable to verify the identity, purity, and sterility of the purchased product — which in practice applies to nearly every buyer on the online market
Interactions
Combining with other unapproved peptides (e.g. BPC-157) in popular "stacking" protocols — without any studies assessing interactions or synergy in humans, covered more extensively in our article on combining BPC-157 and TB-500
Immunosuppressant drugs or other substances affecting angiogenesis — theoretical, unstudied interaction risk given the mechanism of action
No published human pharmacokinetic interaction studies with any medication
Is it worth taking?
Who it's for
- From an editorial standpoint: no group currently exists for whom TB-500 use can honestly be recommended given the current state of evidence
- Anyone considering a tendon or ligament injury should first consult a doctor or physiotherapist and consider methods with confirmed clinical effectiveness
- Anyone who nonetheless decides to experiment should understand they're taking part in an uncontrolled self-experiment, not a therapy with a verified safety profile
Not for
- History of cancer or elevated oncological risk — due to the theoretical risk of excessive angiogenesis
- Pregnancy and breastfeeding — no safety data of any kind
- Athletes subject to doping control — the peptide hormone/growth factor category is banned by WADA year-round
- Anyone unable to verify the identity, purity, and sterility of the purchased product — which in practice applies to nearly every buyer on the online market
Evidence
Worth knowing
There is no single, consistent chemical definition in the scientific literature for the substance actually sold as "TB-500."
The most current scoping review (2026) identified only one study directly concerning TB-500 itself — the rest of the literature concerns full-length thymosin beta-4.
Full-length thymosin beta-4 (RGN-137) went through Phase II clinical trials for chronic wounds but never obtained drug registration, and its development was halted.
The broad peptide hormone/growth factor category TB-500 is sometimes grouped with sits on WADA's year-round prohibited list.
Studies
Direct evidence on TB-500 was limited to a single identified study — the remaining literature concerned full-length thymosin beta-4, and musculoskeletal tissue categories such as tendon and ligament were only sparsely represented in the reviewed literature.
McGuire F et al., Applied Sciences, 2026 (scoping review)
Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review
Early-stage evidenceMcGuire F, Hughes E, Maak T, Cushman DM · Applied Sciences · 2026
A systematic scoping review searching PubMed, Europe PMC, and ClinicalTrials.gov through March 2026, identifying 80 eligible publications on thymosin beta-4 and TB-500. Evidence was predominantly preclinical (animal models and in vitro), concerned mainly full-length Tβ4 rather than the TB-500 fragment itself, and direct TB-500 evidence was limited to one identified study. Musculoskeletal tissue categories (tendon, ligament, muscle, cartilage) were sparsely represented relative to skin and corneal wounds.
View studyThymosin beta4: actin-sequestering protein moonlights to repair injured tissues
Moderate evidenceGoldstein AL, Hannappel E, Kleinman HK · Trends in Molecular Medicine · 2005
A review of the biochemistry and biology of full-length thymosin beta-4 as the main intracellular actin-sequestering protein, describing its role in skin and corneal healing and potential clinical applications in tissue repair after ischemia. Concerns only the full molecule, not the short fragment sold as TB-500.
View studySimultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro
Early-stage evidenceZhang Y et al. · Journal of Pharmaceutical and Biomedical Analysis (methodological study) · 2024
One of the few studies attempting to pharmacokinetically and biologically characterize a substance actually matching the name TB-500, using high-resolution mass spectrometry in vitro and in rats. Pro-healing activity was confirmed in cell assays, but the study did not involve humans and did not assess tendon or ligament healing.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
196 publications on this site
Medical review
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
268 publications on this site
Related entries
4.1GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper tripeptide with one of the longest and best-documented track records in this category for topical skin use — but that solid cosmetic reputation is often groundlessly extended to injectable, systemic use, for which human evidence is practically nonexistent.
4.5Growth Hormone (GH)
A peptide hormone responsible for growth in childhood and tissue regeneration throughout life — surrounded by a dense web of marketing myths about supplements supposedly 'releasing GH.'
2.8Melanotan II
Melanotan II is an unapproved, injectable peptide promoted for "sunless tanning" through direct melanocyte stimulation — a substance with documented, serious adverse effects (from priapism to melanoma cases), banned or flagged by health agencies in multiple countries. This entry is deliberately written with an emphasis on risk, because the evidence of real harm here is far more solid than the evidence for any safe use.
4.4Heart Rate Variability (HRV)
The variability in the time between successive heartbeats is one of the best non-invasive indicators of autonomic nervous system balance — today available in nearly every sports watch.
4.2Red Light Therapy (Photobiomodulation)
Exposure to red and near-infrared light has become a popular biohacking tool — with real, though still limited, evidence mainly in the context of skin health.
4.8Sleep
Sleep isn't a passive shutdown of the body — it's an active, highly organized biological process. Its shortfall (and, counterintuitively, its excess too) is linked to a measurably higher risk of death from any cause.
4.7Sauna (Thermal Heat Therapy)
Regular sauna use is linked in cohort studies to lower cardiovascular mortality risk — the strongest data comes from Finland.
Related articles
PoradnikiBPC-157: What Is Actually Known About the "Regenerative Peptide" — and What Isn't
BPC-157 is often described online as a near-miraculous peptide for tendon, ligament, and joint injuries — regenerating tissue where other methods fail. The problem is that almost this entire reputation rests on rodent studies. Clinical data in humans is extremely limited, the substance isn't approved by any drug agency, and in many countries it's sold in a legal gray area as a "research compound" rather than a drug or supplement. This article is deliberately skeptical — because the evidence that actually exists deserves skepticism.
September 4, 2026
PoradnikiPeptide Therapy: Overview and Safety — What's a Drug, and What's a Gray Market
"Peptides" has become a catch-all buzzword in biohacking covering both real, FDA-approved drugs and hundreds of substances sold online as "research use only" — with no oversight of quality, sterility, or dosing. This article pulls the two apart: we check which peptides actually made it through drug approval, which are circulating in a legal gray zone, and what real risk comes with the second group.
September 16, 2026
PoradnikiBPC-157 and TB-500 Together: Does Stacking These Peptides Make Scientific Sense?
The "Wolverine stack" — combining BPC-157 and TB-500 in a single regenerative protocol — is one of the most popular "combos" in peptide biohacking. Marketing presents it as a natural complement: one peptide works locally, the other systemically. The problem is that neither peptide, alone or especially together, has a single human clinical trial behind it — and the theory about their mutual reinforcement is a hypothesis drawn from separate rat studies, not the result of a comparative trial.
October 5, 2026
PoradnikiWhole-Body Cryotherapy: Does It Actually Work, or Is It Just a Pricier Cold Shower?
Cryotherapy chambers, where the temperature drops to -110°C or lower, promise faster recovery, less inflammation, and reduced muscle soreness after training — for a single session that can cost a fair amount of money. The latest meta-analyses, however, paint a more nuanced picture than wellness-industry marketing suggests: a real anti-inflammatory effect does exist, but the evidence for reducing muscle soreness right after exercise is much weaker than commonly assumed.
September 16, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.